ETON
Eton Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$49.22
−2.17%Year over year
Reported trailing growth
- Revenue
- +81.5%
- EBITDA
- +835.3%
- EBIT
- +2120.9%
- EPS
- +403.3%
- Free cash flow
- +20.5%
- Operating cash flow
- +23.7%
Forward estimates
Based on analyst estimates
- Revenue
- +98.7%
- EBITDA
- +276.7%
- EPS
- +245.3%
Three-year CAGR
- Revenue
- +55.5%
- EBITDA
- +348.6%
- EBIT
- +102.8%
- Net income
- -20.4%
- EPS
- -13.3%
- Free cash flow
- +71.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026